The false savings — and cruelty — of cutting GLP-1 coverage in Massachusetts
Posted
By Courtney Desy
I AM PROTECTED by a diagnosis.
After I began taking a GLP-1–based medication, my A1C fell from 12 to 6 within months. Because I have type 2 diabetes, my insurance continues to cover the drug. Patients receiving medications from the same class to treat obesity may not have that protection—even when treatment is producing measurable health improvements.
Thousands of Massachusetts residents now face losing access. This summer, MassHealth, the state Medicaid program that insures low-income residents, ended coverage for medications prescribed solely to treat obesity, affecting approximately 22,000 members. The state’s Group Insurance Commission, which oversees coverage for public employees, has done the same, a move that affects about the same number of people. Private insurers across the Commonwealth have also restricted obesity coverage while generally preserving it for diabetes.
Nothing about these medications’ effectiveness changed. What changed was who would pay for them—and therefore who could continue receiving them.
The United States spends more per person on health care than other wealthy countries without achieving correspondingly better outcomes. Yet Massachusetts insurers are withdrawing coverage for a medication class that produces measurable health improvements.
These medications do far more than change how people look. They can improve blood sugar, cardiovascular risk factors, sleep apnea, and mobility. The Food and Drug Administration approved the GLP-1 drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity after clinical trials demonstrated meaningful improvement. In a separate large trial, another GLP-1 medication, semaglutide, reduced major cardiovascular events by 20 percent among adults with overweight or obesity and established cardiovascular disease who did not have diabetes.
These are the outcomes our expensive health care system should be trying to achieve.
Insurers and state officials face a real affordability problem. These medications remain expensive, many patients could qualify, and treatment may be needed long term. Massachusetts insurers have cited coverage restrictions among factors contributing to stronger financial results in 2026. Point32Health estimated that its restrictions could save $100 million or more this year.
As a CPA, I understand why those figures command attention. As a nurse, I question a calculation that recognizes the immediate cost of treatment more readily than the future cost of disease.
The reductions may save insurers money, but Massachusetts consumers should not expect meaningful premium relief. State regulators have approved an average 10.4 percent premium increase for 2027 in the individual and small-group market.
Patients are losing treatment. Insurers are recording savings. Premiums are still increasing. What health care outcome is this strategy designed to achieve?
When coverage forces treatment to stop, the consequences are predictable. One year after semaglutide treatment ended, trial participants had regained two-thirds of the weight they had lost, while most improvements in blood pressure, blood sugar, cholesterol, and other cardiometabolic measures moved back toward baseline. In a trial of the GLP-1 drug tirzepatide, participants who were switched to placebo regained an average of 14 percent of their body weight during the following year, while those who continued treatment lost another 5.5 percent.
Ending coverage does not merely stop progress. It reverses it—and costs may return as diabetes, CPAP equipment, additional medications, disability, and hospital care.
The insurer paying for treatment today may not cover those consequences years from now. Patients change jobs, health plans, and eligibility. One organization can capture immediate savings while another payer—or the patient—absorbs the later cost. That is cost transfer, not necessarily cost reduction.
It also risks deepening inequality. Nearly 1 million Massachusetts residents rely on SNAP to help afford food. For households already balancing food, housing, utilities, and medical expenses, another three-figure monthly bill for a costly medication may be impossible. Continued treatment becomes increasingly dependent on who can afford it.
Massachusetts should confront excessive drug prices directly by negotiating lower prices, using evidence-based eligibility requirements, and preserving coverage for patients demonstrating meaningful improvement. It should not force patients to regain weight or develop diabetes before treatment becomes worthy of coverage.
Massachusetts regulators should also require health plans that restrict coverage to report how many patients lose treatment, what happens to their health afterward, and whether projected pharmacy savings are offset by higher medical spending elsewhere. Without that accounting, the Commonwealth cannot know whether it is controlling health care costs or simply shifting them to patients, families, and future payers.
My diagnosis protects my access to a medication class that transformed my health. I am grateful. But I cannot accept a system that offers another patient less protection because treatment worked before diabetes developed—or because that patient cannot afford to purchase better health privately.
In a state known for health care innovation, saving insurers money should not be mistaken for improving health. Massachusetts should demand both affordability and access.
